Article Title: Cystitis-Related Bladder Pain Involves ATP-Dependent HMGB1 Release from Macrophages and Its Downstream H2S/Cav3.2 Signaling in Mice
Figure Lengend Snippet: Effect of T-type Ca 2+ channel blockers and genetic deletion of Ca v 3.2 on CPA-induced bladder pain-like nociceptive behavior ( A , D , G , J ), referred hyperalgesia ( B , E , H , K ) and bladder swelling ( C , F , I , L ) in mice. ( A – F ) In ddY mice, 6-prenylnaringenin (6-PNG), a hop-derived T-type Ca 2+ channel blocker, or KTt-45, a derivative of 6-PNG, at 10 and 30 mg/kg was administered i.p. 3 h 15 min after i.p. CPA at 400 mg/kg. ( G – I ) In C57BL/6 mice, TTA-A2 at 1 mg/kg was administered i.p. 3 h after the CPA treatment. ( J – L ) CPA at 400 mg/kg was administered i.p. to wild-type (WT) and Ca v 3.2-knockout mice (KO) of a C57BL/6J background. Nociceptive behaviors were counted for 30 min starting 3.5 h after CPA treatment, followed immediately by evaluation of referred hyperalgesia/allodynia and then measurement of wet tissue weight of the excised bladder. V, vehicle. Data show the mean with S.E.M. for 6–8 (A–C), 5 (D–F), 5–6 (G–I) or 6 (J–L) mice. * p
Article Snippet: TTA-A2 was obtained from Alomone Labs. (Jerusalem, Israel), and A438079, 5-BDBD and AZ 10606120 were from Tocris Bioscience (Bristol, UK). (2R/S)-6-Prenylnaringenin (6-PNG) and KTt-45 [6-(3-ethylpent-2-enyl)-5,7-dihydroxy-2-(2-hydroxyphenyl)chroman-4-one] were synthesized in-house, as reported previously [ ].
Techniques: Mouse Assay, Derivative Assay, Knock-Out